

**Guideline:** Colorectal Cancer (CRC) (update) Committee meeting 12

**Date:** 24 April 2019

**Location:** RCOG offices, London

**Minutes:** Confirmed

<b>Committee members present:</b>	
Peter Hoskin (Chair)	(Present for notes 1–6)
Justin Davies (Topic Adviser)	(Present for notes 1–6)
Cindy Chew	(Present for notes 1–6)
Julie Hepburn	(Present for notes 1–6)
Vivek Misra	(Present for notes 1–6)
Richard Roope	(Present for notes 1–6)
Kevin Monahan	(Present for notes 1–6)
Manuel Salto-Tellez (Co-optee)	(Present for notes 1–6)
Michael Braun	(Present for notes 1–6)
Baljit Singh	(Present for notes 1–6)
Charlotte Dawson	(Present for notes 1–6)
Stephen Fenwick (Co-optee)	(Present for notes 1–6)
Michael Shackcloth (Co-optee)	(Present for notes 1–6)
Faheez Mohamed (Co-optee)	(Present for notes 1–6)
Gemma Burgess (Co-optee)	(Present for notes 1–6)

<b>In attendance:</b>		
Maija Kallioinen	NGA Guideline Lead	(Present for notes 1–6)
Charlene Dixon	NGA Project Manager	(Present for notes 1–6)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 3–6)
Ted Barker	NGA Systematic Reviewer	(Present for notes 1–6)
Justine Karpusheff	NICE Guideline Commissioning Manager	(Present via teleconference for notes 3)
Gareth Haman	NICE Editor	(Present via teleconference for notes 3)

<b>Apologies:</b>	
Debby Lennard	GC member
Jay Bradbury	GC member
Ratan Verma	Co-opted member
James Hawkins	NGA Senior Health Economist
Louise Crathorne	NGA Senior Systematic Reviewer

## **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the 12<sup>th</sup> meeting on Colorectal Cancer guideline (update). The Committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included: evidence report update from searches, guideline sign off- recommendations and rationale and impact sections, research recs sign off, equality impact assessments and NICE publications policy.

## **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the

last meeting.

<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Stephen Fenwick	Co-optee committee member (Hepatobiliary surgeon)	Principle Investigator for PURASTAT trial - Post-Market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Liver Surgery. Funding received for department.	Indirect, financial	Declare and participate
Stephen Fenwick	Co-optee committee member (Hepatobiliary surgeon)	Invited speaker to Russian Oncology Conference (sponsored by Merck) on June 21st 2019 The talk is on the topic of downsizing to resectability in the management of colorectal cancer liver metastases. This topic has not been specifically covered in the guideline.	Direct, financial	Declare and participate
Richard Roope	Committee member (GP)	Member of RCGP Quality Outcome Framework (QOF) Quality Improvement Advisory Group	Direct, non-financial	Declare and participate
Mike Shackcloth	Co-opted member (Thoracic Surgeon)	Co-investigator on a neo-adjuvant TKI study in lung cancer funded by Astra-Zenica	Direct, non-financial	Declare and participate
Vivek Misra	Committee member (Oncologist)	Presentation of The Christie rectal contact radiotherapy outcomes data to the GEC ESTRO/ICONE meeting in Milan. Travel and accommodation paid for from the study budget at The Christie.	Direct, financial	Declare and participate
Cindy	Committee member	Hospital Sub-Dean for Glasgow University and	Direct, financial	Declare and participate

Chew	(Radiologist)	Hairmyres Hospital		
Kevin Monahan	Committee member (Gastroenterologist)	New publications: Cavazza A, Radia C, Harlow C, Monahan KJ. Experience of the implementation and outcomes of universal testing for Lynch syndrome in the United Kingdom. Colorectal Dis. 2019 Feb 28. doi: 10.1111/codi.14597. [Epub ahead of print] Adams LK, Qiu S, Hunt AK, Monahan KJ. A dedicated high-quality service for the management of patients with an inherited risk of colorectal cancer. Colorectal Dis. 2019 Mar 23. doi: 10.1111/codi.14622. [Epub ahead of print]	Direct, non-financial	Declare and participate
Justin Davies	Topic Adviser (Colorectal Surgeon)	Examiner –European Board of Surgery Qualification (EBSQ) in Coloproctology	Direct, financial	Declare and participate
Manuel Salto Tellez	Co-opted committee member (Molecular Pathologist)	Co PI in a project to develop a test in colorectal cancer to score immune biomarkers of prognosis. This is supported by a mixture of government funding (Innovate UK) and industry (Philips). If successful, Philips will have first-right to buy this product from us. The benefits will go back to the NHS. No personal payment goes to Salto-Tellez or other members of this programme in relation to this activity.	Indirect, financial	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of last meeting**

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

It was pointed out that there were three different JH's the previous minutes.

### **3. Presentations**

The Chair introduced Maija Kallioinen, NGA Guideline lead, who discussed the possibility of developing an algorithm for the guideline. The Committee agreed that when recommendations are reviewed, the committee will keep this in mind and flag any recs or sections where an algorithm might be useful.

Maija then went on to discuss research recs. The Committee reviewed the draft research recommendations and made some edits.

The Chair introduced Nathan Bromham from the NGA reviewing team, who discussed the evidence from update searches. It was concluded that none of the new studies would change conclusions already made.

The Chair thanked Nathan for his presentation..

The Chair introduced Maija Kallioinen, NGA Guideline lead, who lead the discussion on signing off recommendations and rationale and impact sections in the guideline.

The Committee went through the whole guideline document and signed off the recommendations and rationale and impact sections.

Maija Kallioinen then discussed the NICE Centre for Guidelines Publications Policy with the Committee.

Maija Kallioinen the led the discussion on the Equality Impact Assessment. It was agreed that the recs should not put any groups into a disadvantaged position.

### **4. Any other business**

GC13 in October to be held a little later so that a committee dinner can be held afterwards.

**Date of next meeting:** 11<sup>th</sup> October 2019

**Location of next meeting:** RCOG, London